Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chinese pharma unaffected by drug recalls
According to the FDA, approximately 19 people have died recently from allergic reactions linked to contaminated shipments of heparin, a blood thinner, imported from China. China itself has
According to the FDA, approximately 19 people have died recently from allergic reactions linked to contaminated shipments of heparin, a blood thinner, imported from China. China itself has
The UK-based drug major is offering its medicines at variable prices in India, Morocco, South Africa and other developing nations, to tap into their large segments of middle
The submission in Japan includes four clinical studies that were part of the original new drug application in the US, including the randomized, pivotal Phase III multicenter, comparative
Revenues for 2007 were $14 million, down 26 % from $18.9 million in 2006 primarily as a result of the successful completion of the one-time production of clinical-grade
Revenue for the six months ended January 31, 2008 was $73.3 million compared with $45.4 million in the same period of 2007. Net income for the current quarter
For the year ended December 31, 2007, the net loss was $118,000, or $0.01 per share basic and diluted, compared with net loss of $481,000, or $0.03 per
The net loss for the fourth quarter of 2007 was $6.8 million compared to $8 million in the fourth quarter of 2006. The net loss for 2007 was
The increase in net losses for the year is attributable to increased expenditures in research and development of products in the company’s pipeline and to accounting requirements for
Revenues for the fourth quarter were $35.7 million compared to $33.7 million in the third quarter, 2007, an increase of 6% quarter on quarter. Excluding the impact of
Net loss for the 12-month period decreased to $2 million or $0.04 per share in 2007 from $3.4 million or $0.07 per share in 2006, due to better